- Doesch, A.O., Zhao, L., Gleissner, C.A., Akhavanpoor, M., Rohde, D., Okuyucu, D., Hakimi, M., Dengler, T.J., Katus, H.A., Erbel, C. 2014. Inhibition of B7-1 (CD80) by RhuDex(®) reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions. Drug Des Devel Ther, 8:447-57.
- Erbel, C., Okuyucu, D., Akhavanpoor, M., Zhao, L., Wangler, S., Hakimi, M., Doesch, A., Dengler, T.J., Katus, H.A., Gleissner, C.A. 2014. A human ex vivo atherosclerotic plaque model to study lesion biology. J Vis Exp, (87).
- Shaked, I., Hanna, D.B., Gleißner, C., Marsh, B., Plants, J., Tracy, D., Anastos, K., Cohen, M., Golub, E.T., Karim, R., Lazar, J., Prasad, V., Tien, P.C., Young, M.A., Landay, A.L., Kaplan, R.C., Ley, K. 2014. Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol, 34(5):1085-92.
- Erbel, C., Tyka, M., Helmes, C.M., Akhavanpoor, M., Rupp, G., Domschke, G., Linden, F., Wolf, A., Doesch, A., Lasitschka, F., Katus, H.A., Gleissner, C.A. 2014. CXCL4-induced plaque macrophages can be specifically identified by co-expression of MMP7+S100A8+ in vitro and in vivo. Innate Immunity, [Epub ahead of print]
- Kraeuter, M., Helmschrott, M., Erbel, C., Gleissner, C.A., Frankenstein, L., Schmack, B., Ruhparwar, A., Ehlermann, P., Katus, H.A., Doesch, A.O. 2013. Conversion to generic cyclosporine A in stable chronic patients after heart transplantation. Drug Des Devel Ther, 7:1421-6.
- Cornu, C., Dufays, C., Gaillard, S., Gueyffier, F., Redonnet, M., Sebbag, L., Roussoulières, A., CGleissner, C.A., Groetzner, J., Lehmkuhl, H.B., Potena, L., Gullestad, L., Cantarovich, M., Boissonnat, P. Impact of the Reduction of Calcineurin Inhibitors on Renal Function in Heart Transplant Patients: A Systematic Review and Meta-Analysis. 2013. Br J Clin Pharmacol, [Epub ahead of print]
- Kraeuter, M., Helmschrott, M., Erbel, C., Gleissner ,C.A., Frankenstein, L., Schmack, B., Ruhparwar, A., Ehlermann, P., Katus, H.A., Doesch, A.O. 2013. Conversion to generic cyclosporine A in stable chronic patients after heart transplantation. Drug Des Devel Ther, 7:1421-6.
- Doesch, A.O., Mueller, S., Erbel, C., Gleissner, C.A., Frankenstein, L., Hardt, S., Ruhparwar, A., Ehlermann, P., Dengler, T., Katus, H.A. 2013. Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study. Drug Des Devel Ther, 2013 7:1323-8.
- Erbel, C., Rupp, G., Helmes, C.M., Tyka, M., Linden, F., Doesch, A.O., Katus, H.A., Gleissner ,C.A. 2013. An in vitro model to study heterogeneity of human macrophage differentiation and polarization. J Vis Exp. (76).
- Gueler, I., Mueller, S., Helmschrott, M., Oeing, C.U., Erbel, C., Frankenstein, L., Gleissner, C., Ruhpawar, A., Ehlermann, P., Dengler, T.J., Katus, H.A., Doesch, A.O. 2013. Effects of vildagliptin (Galvus ®) therapy in patients with type 2 diabetes mellitus after heart transplantation. Drug Des Devel Ther, 7:297-303.
- Erbel, C., Taskin, R., Doesch, A., Dengler, T.J., Wangler, S., Akhavanpoor, M., Ruhpawar, A., Giannitsis, E., Katus, H.A., Gleissner, C.A. 2013. High sensitive troponin T measurements early after heart transplantation predict shot and long term survival. Transplantation, 26(3):267-72.
- Doesch, A.O., Repp, J., Hofmann, N., Erbel, C. Frankenstein, L., Gleissner, C.A., Schmidt, C., Ruhpawar, A., Zugck, C., Schnitzler, P., Ehlermann, P., Dengler, T.J., Katus, H.A. 2012. Effects of oral Valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients. Drug Des Devel Ther, 6:289-95.
- Korosoglou, G., Gleissner, C.A., Giannitsis, E., Katus, H.A. 2012. Subclinical atherosclerosis and chronic troponin elevation: the voice of silence in diabetics. J Am Coll Cardiol, 60(2):167-8.
- Erbel, C., Achenbach, J., Dengler, T.J., Lasitschka, F., Gleissner, C.A., Bea, F., Katus, H.A., Szabo, G. 2011. PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels. Eur J Med Res, 16(8):367-74.
- Erbel, C., Dengler, T.J., Wangler, S., Bea, F. Wambsganss, N., Hakimi, M., Böckler, D., Katus, H.A., Gleissner, C.A. 2010. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol, 106(1), 125-34.
- Gleissner, C.A., Little, K.M., Ley, K. 2010. CXCL4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol, 184 (9), 4810-8.
- Schulz, C., Heuschen, N.V., Fröhlich, T., Lorenz, M., Pfeiler, S., Gleissner, C.A., Kremmer, E., Kessler, M., Khandogau A.G., Engelmann, B., Ley, K., Massberg, S., Arnold, G.J. 2010. Identification of novel downstream targets of platelet glycoprotein VI activation. Blood, 115(20):4102-10.
- Gleissner, C.A., Shaked, I., Erbel, C., Böckler, D., Katus, H.A., Ley, K. 2010. CXCL4 induces CD163- macrophages: Functional implication in atherosclerosis. Circ Res, 106(1):203-11.
- Konstandin, M.H., Doesch, A., Ammon, K., Wabnitz, G.H., Gleissner, C.A., Koch, A., Remppis, A., Katus, H.A., Dengler, T.J. 2008. Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy. Clin Transplant, 22(5):639-44.
- Gleissner, C.A., Sanders, J.M., Nadler, J.L., Ley, K. 2007. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol, 28(6):1137-43.
- Cho, H.J., Shashkin, P., Gleissner, C.A., Dunson, D., Jain, N., Lee, J., Miller, Y., Ley, K. 2007. Induction of dendritic cell-like phenotype in macrophages during foam cell formation. Physiol Genomics, 29(2):149-160.
- Gleissner, C.A., Zastrow, A., Klingenberg, R., Kluger, M.S., Konstandin, M., Celik, S., Haemmerling, S., Shankar, V., Giese, T., Katus, H.A., Dengler, T.J. 2007. IL-10 inhibits endothelium-dependent T-cell costimulation by upregulation of ILT3/4 in human vascular endo-thelial cells. Eur J Immunol, 37(1):177-192.
- Gleissner, C.A., Doesch, A., Ehlermann, P., Koch, A., Sack, F.U., Katus, H.A., and Dengler, T.J. 2006. Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy. Am J Transplant, 6(11):2750-2758.
- Gleissner, C.A., Klingenberg, R., Staritz, P., Koch, A., Ehlermann, P., Wiggenhauser, A., and Dengler, T.J. 2006. Role of erythropoietin in anemia after heart transplantation. Int J Cardiol 112(3):341-347.
- Klingenberg, R., Gleissner, C., Koch, A., Schnabel, P.A., Sack, F.U., Zimmermann, R., Katus, H.A., and Dengler, T.J. 2005. Impact of pre-operative diabetes mellitus upon early and late survival after heart transplantation: a possible era effect. J Heart Lung Transplant 24(9):1239-1246.
- Klingenberg, R., Autschbach, F., Gleissner, C., Giese, T., Wambsganss, N., Sommer, N., Richter, G., Katus, H.A., and Dengler, T.J. 2005. Endothelial inducible costimulator ligand expression is increased during human cardiac allograft rejection and regulates endothelial cell-dependent allo-activation of CD8+ T cells in vitro. Eur J Immunol 35(6):1712-1721.
- Klingenberg, R., Koch, A., Gleissner, C., Schnabel, P.A., Haass, M., Remppis, A., Katus, H.A., and Dengler, T.J. 2005. Determinants of B-type natriuretic peptide plasma levels in the chronic phase after heart transplantation. Transpl Int 18(2):169-176.
- Gleissner, C.A., Murat, A., Schafer, S., Klingenberg, R., Koch, A., Remppis, A., Zimmermann, R., Katus, H.A., and Dengler, T.J. 2004. Reduced hemoglobin after heart transplantation is no independent risk factor for survival but is associated closely with impaired renal function. Transplantation 77(5):710-717.
- Gleissner, C.A., Klingenberg, R., Nottmeyer, W., Zipfel, S., Sack, F.U., Schnabel, P.A., Haass, M., and Dengler, T.J. 2003. Diagnostic efficiency of rejection monitoring after heart transplantation with cardiac troponin T is improved in specific patient subgroups. Clin Transplant 17(3):284-291.
- Gleissner, C.A., Zehelein, J., Sack, F.U., Schnabel, P., Haass, M., and Dengler, T.J. 2002. Extended experience and subgroup analysis using cardiac troponin T for rejection monitoring after heart transplantation. Transplant Proc 34(6):2178-2180.